| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -297.1 | -212.8 |
| EPS (diluted, $ a share) | $-1.99 | $-1.56 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PCVX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vaxcyte, Inc.: key numbers
- Share price
- $61.61Close, Nov 16
- Market cap
- $9.75B
- Shares outstanding
- 158.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vaxcyte, Inc.
All →Vaxcyte Chief Technical Ops Officer Harpreet S. Dhaliwal Sells $1.15M of Stock
Harpreet S. Dhaliwal, Chief Technical Ops Officer, sold 17,000 shares of Vaxcyte, Inc. at $67.33 to $68.82 a share (average $67.83) in 3 transactions, worth $1.15M in total on Nov 11, 2026. Shares held after the trade: 68,085 (-0.8%).
- Value
- $1.15M
- Shares
- 17,000
- Average price
- $67.83
- Role
- Chief Technical Ops Officer
- Holding change
- -0.8%
- Trade date
- Nov 11, 2026
Vaxcyte SVP, Finance & CAO Elvia Cowan Sells $183K of Stock
Elvia Cowan, SVP, Finance & CAO, sold 3,000 shares of Vaxcyte, Inc. at $60.77 to $61.55 a share (average $60.92) in 2 transactions, worth $183K in total on Nov 2, 2026. Shares held after the trade: 27,860 (-2.1%).
- Value
- $183K
- Shares
- 3,000
- Average price
- $60.92
- Role
- SVP, Finance & CAO
- Holding change
- -2.1%
- Trade date
- Nov 2, 2026
Vaxcyte EVP, Chief Scientific Ofc, COO Jim Wassil Sells $137K of Stock
Jim Wassil, EVP, Chief Scientific Ofc, COO, sold 2,250 shares of Vaxcyte, Inc. at $60.78 to $61.57 a share (average $60.90) in 2 transactions, worth $137K in total on Nov 2, 2026. Shares held after the trade: 145,435 (-0.2%).
- Value
- $137K
- Shares
- 2,250
- Average price
- $60.90
- Role
- EVP, Chief Scientific Ofc, COO
- Holding change
- -0.2%
- Trade date
- Nov 2, 2026
Vaxcyte Financial Results
Vaxcyte reported third quarter 2026 financial results and provided a business update, highlighting positive topline Phase 3 data for its VAX-31 adult pneumococcal vaccine candidate. The company strengthened its balance sheet with $1.1 billion in net proceeds from October equity and debt offerings, resulting in a pro forma cash position of approximately $3.4 billion. Vaxcyte remains on track for a planned BLA submission for VAX-31 in the first half of 2028.
- Term
- Q3 2026
“The positive topline results from OPUS-1 represent a significant milestone for Vaxcyte and our broad-spectrum pneumococcal conjugate vaccine (PCV) franchise. VAX-31 met all prespecified primary endpoints in this pivotal Phase 3 trial, which inaugurated a more stringent noninferiority standard, and we believe the results further support its potential best-in-class profile.”
Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte
“Following our positive OPUS-1 results, we completed concurrent equity and convertible senior notes offerings, raising approximately $1.1 billion in net proceeds, to further strengthen our balance sheet and extend our cash runway. With approximately $3.4 billion in pro forma cash, cash equivalents and investments as of September 30, 2026, we are well positioned to support the potential U.S. commercial launch of VAX-31 for adults and advance our other key initiatives.”
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte
Vaxcyte $575M Debt Financing with U.S. Bank Trust Company, National Association
Vaxcyte, Inc. completed the sale and issuance of $575 million in 1.50% Convertible Senior Notes due 2032. The notes are senior unsecured obligations with an initial conversion price of approximately $89.60 per share of common stock. The company intends to use the proceeds for general corporate purposes, which may include research and development and working capital.
- Value
- $575M
- Counterparty
- U.S. Bank Trust Company, National Association
- Term
- through Oct 2032
Vaxcyte EVP, Chief Scientific Ofc, COO Jim Wassil Sells $1.56M of Stock
Jim Wassil, EVP, Chief Scientific Ofc, COO, sold 18,000 shares of Vaxcyte, Inc. at $86.74 a share, worth $1.56M in total on Oct 5, 2026. Shares held after the trade: 145,435 (-11.0%).
- Value
- $1.56M
- Shares
- 18,000
- Price
- $86.74
- Role
- EVP, Chief Scientific Ofc, COO
- Holding change
- -11.0%
- Trade date
- Oct 5, 2026